These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 25393310)
1. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer. Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310 [TBL] [Abstract][Full Text] [Related]
2. Claudin expression in breast cancer: high or low, what to expect? Ricardo S; Gerhard R; Cameselle-Teijeiro JF; Schmitt F; Paredes J Histol Histopathol; 2012 Oct; 27(10):1283-95. PubMed ID: 22936447 [TBL] [Abstract][Full Text] [Related]
3. Expression patterns of claudins in patients with triple-negative breast cancer are associated with nodal metastasis and worse outcome. Katayama A; Handa T; Komatsu K; Togo M; Horiguchi J; Nishiyama M; Oyama T Pathol Int; 2017 Aug; 67(8):404-413. PubMed ID: 28699235 [TBL] [Abstract][Full Text] [Related]
4. The prognostic role of claudins -1 and -4 in oral squamous cell carcinoma. DE Vicente JC; Fernández-Valle Á; Vivanco-Allende B; Santamarta TR; Lequerica-Fernández P; Hernández-Vallejo G; Allonca-Campa E Anticancer Res; 2015 May; 35(5):2949-59. PubMed ID: 25964581 [TBL] [Abstract][Full Text] [Related]
5. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Choi JE; Kang SH; Lee SJ; Bae YK Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503 [TBL] [Abstract][Full Text] [Related]
6. Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients' survival. Bouchagier KA; Assimakopoulos SF; Karavias DD; Maroulis I; Tzelepi V; Kalofonos H; Karavias DD; Kardamakis D; Scopa CD; Tsamandas AC In Vivo; 2014; 28(3):315-26. PubMed ID: 24815833 [TBL] [Abstract][Full Text] [Related]
7. Claudin-1 Protein Expression Is a Good Prognostic Factor in Non-Small Cell Lung Cancer, but only in Squamous Cell Carcinoma Cases. Moldvay J; Fábián K; Jäckel M; Németh Z; Bogos K; Furák J; Tiszlavicz L; Fillinger J; Döme B; Schaff Z Pathol Oncol Res; 2017 Jan; 23(1):151-156. PubMed ID: 27687058 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India. Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142 [TBL] [Abstract][Full Text] [Related]
9. Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Morohashi S; Kusumi T; Sato F; Odagiri H; Chiba H; Yoshihara S; Hakamada K; Sasaki M; Kijima H Int J Mol Med; 2007 Aug; 20(2):139-43. PubMed ID: 17611630 [TBL] [Abstract][Full Text] [Related]
10. [Claudins as prognostic factors of breast cancer]. Szász MA Magy Onkol; 2012 Sep; 56(3):209-12. PubMed ID: 23139925 [TBL] [Abstract][Full Text] [Related]
11. High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer. Jääskeläinen A; Soini Y; Jukkola-Vuorinen A; Auvinen P; Haapasaari KM; Karihtala P BMC Cancer; 2018 Feb; 18(1):223. PubMed ID: 29482498 [TBL] [Abstract][Full Text] [Related]
12. Identification of claudin‑1, ‑3, ‑7 and ‑8 as prognostic markers in human laryngeal carcinoma. Zhou S; Piao X; Wang C; Wang R; Song Z Mol Med Rep; 2019 Jul; 20(1):393-400. PubMed ID: 31115553 [TBL] [Abstract][Full Text] [Related]
13. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602 [TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in Hu A; Li J; Ruan S; Fan Y; Liao Y Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30910845 [No Abstract] [Full Text] [Related]
15. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients. Ricciardi GR; Adamo B; Ieni A; Licata L; Cardia R; Ferraro G; Franchina T; Tuccari G; Adamo V PLoS One; 2015; 10(6):e0128368. PubMed ID: 26039245 [TBL] [Abstract][Full Text] [Related]
16. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression. Abd-Elazeem MA; Abd-Elazeem MA Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318 [TBL] [Abstract][Full Text] [Related]